Question 1

Do I qualify for Zepbound™ (Tirzepatide) treatment?

Accepted Answer

Insurance coverage for Zepbound™ generally requires BMI ≥ 30 (obesity), OR BMI ≥ 27 with a weight-related comorbidity like Obstructive Sleep Apnea (OSA), Type 2 diabetes, or hypertension. Determining whether you meet that bar is exactly what our screening does. We provide the FDA-grade sleep testing required to document sleep apnea as a qualifying comorbidity, then refer you to a weight-loss provider who can write the prescription. Dr. Jain's expertise as a National Key Opinion Leader means the clinical documentation we hand over is the kind insurers accept.

Question 2

How much weight can I expect to lose with Zepbound™?

Accepted Answer

SURMOUNT clinical trials demonstrated average weight loss of 15-21% of body weight over 72 weeks, with higher doses producing greater results. For sleep apnea patients, even 10-15% weight loss can significantly reduce AHI (apnea-hypopnea index) and improve oxygen levels. Individual results vary based on starting weight, adherence, lifestyle modifications, and metabolic factors. Dr. Jain uses longitudinal sleep testing to objectively track whether weight loss is producing meaningful improvements in your airway function.

Question 3

What is the SURMOUNT-OSA trial and why does it matter?

Accepted Answer

SURMOUNT-OSA was a landmark clinical trial demonstrating that Tirzepatide (Zepbound™) significantly reduces sleep apnea severity. Patients achieved average AHI reductions of 27-30 events per hour and improvements in hypoxic burden (oxygen desaturation). This trial led to FDA approval of Zepbound™ for moderate-to-severe obstructive sleep apnea with obesity in December 2024 — not just for weight loss. Dr. Jain presents these findings nationally as a paid speaker for Eli Lilly, and applies them in how we evaluate and monitor sleep apnea patients.

Question 4

Can I stop using CPAP if I lose weight on Zepbound™?

Accepted Answer

Possibly, but it requires careful medical monitoring. Weight loss can significantly reduce or even eliminate sleep apnea in some patients. However, stopping CPAP prematurely is dangerous. We use objective sleep testing to verify your disease has gone into remission before discontinuing therapy. As you lose weight, Dr. Jain adjusts CPAP pressures or Inspire/Genio settings to match your new airway anatomy. Some patients can safely discontinue therapy; others need reduced settings. This requires expert management, not guesswork.

Question 5

Do you run metabolic labs or offer nutrition counseling?

Accepted Answer

We focus on the functional impact of weight loss on your sleep and airway health, using sleep testing as a biomarker for metabolic improvement. For comprehensive metabolic endocrinology (A1C, lipid panels, thyroid function) or detailed nutrition counseling, we refer to our trusted network of endocrinologists and registered dietitians. However, for most sleep apnea patients, the sleep data provides the most critical metric to track therapeutic success.

Question 6

How is Dr. Jain's approach different from med spas offering GLP-1s?

Accepted Answer

Med spas focus on cosmetic weight loss and stop at the prescription. We don't prescribe GLP-1s at all—we handle the sleep medicine half. As a National Key Opinion Leader for Zepbound™, Dr. Jain understands the complex interaction between weight loss and upper airway physiology. We use sleep testing to objectively measure improvement, adjust CPAP/Inspire settings as your airway changes, and provide board-certified medical oversight of your apnea. This isn't about fitting into a dress—it's about reducing cardiovascular risk and potentially achieving sleep apnea remission. That requires physician-level expertise no med spa provides.

Question 7

Will my insurance cover Zepbound™ for sleep apnea?

Accepted Answer

Insurance coverage for GLP-1 medications (Zepbound™, Wegovy, Ozempic) varies significantly by plan. Commercial plans increasingly cover these medications for patients with BMI ≥ 27 + sleep apnea. Medicare coverage is more restrictive. We provide detailed clinical documentation including sleep study results, AHI measurements, oxygen desaturation data, and cardiovascular risk factors to support the prior authorization request your prescriber submits. Dr. Jain's status as a National KOL also helps when insurers request peer-to-peer reviews on the sleep apnea diagnosis.

Question 8

What are the side effects of Zepbound™?

Accepted Answer

Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain—typically mild and improving after the first few weeks. Serious but rare risks include pancreatitis, gallbladder disease, kidney problems, and thyroid C-cell tumors (contraindicated if you have personal or family history of medullary thyroid carcinoma or MEN2 syndrome). The provider who prescribes your Zepbound™ handles informed consent and monitors you for these side effects; our role is monitoring how your sleep apnea responds. Most patients tolerate Tirzepatide well, especially with proper dose titration.

Question 9

How long does Zepbound™ treatment take?

Accepted Answer

Zepbound™ is generally a long-term therapy (12+ months) for sustained weight loss, and your prescriber will set the course. Most patients see meaningful weight loss within 3-6 months, with peak effects at 12-18 months. For sleep apnea patients, we perform follow-up sleep testing at 6-12 months to objectively measure AHI reduction and hypoxic burden improvement. This allows us to adjust CPAP settings, reduce Inspire stimulation levels, or document disease remission. Weight loss maintenance often requires ongoing treatment—discontinuing GLP-1s typically results in weight regain.

Question 10

Can I combine Zepbound™ with Inspire or Genio therapy?

Accepted Answer

Yes, and this is often an ideal strategy. Many patients start Inspire/Genio therapy for immediate apnea control, then add Zepbound™ to address the root cause (excess weight). As you lose weight, your airway opens further, allowing us to reduce stimulation settings and potentially achieve better therapeutic outcomes. Dr. Jain manages this integrated approach carefully—weight loss changes your airway anatomy, so device settings must be adjusted accordingly through follow-up sleep testing and titration. This combined strategy offers both immediate protection and long-term disease modification.

Weight Loss & Sleep Apnea: Zepbound™ Screening

Ready for Better Sleep?

Our Role in Your Zepbound Care

Experience Matters.
Especially with Zepbound™.

The Zepbound™ Indication

Coverage & Qualification

The Clinical Journey

Sleep Testing as a Biomarker

Dynamic Therapy Management

Hate Phone Calls? Text Us Instead.We Reply Fast

Ready for Better Sleep?

Dream Difference

Treatment Options

Common Questions about Weight Loss & Sleep Apnea

Weight Loss & Sleep Apnea: Zepbound™ Screening

Ready for Better Sleep?

Our Role in Your Zepbound Care

Experience Matters. Especially with Zepbound™.

The Zepbound™ Indication

Coverage & Qualification

The Clinical Journey

Sleep Testing as a Biomarker

Dynamic Therapy Management

Hate Phone Calls? Text Us Instead.We Reply Fast

Ready for Better Sleep?

Dream Difference

Treatment Options

Common Questions about Weight Loss & Sleep Apnea

Experience Matters.
Especially with Zepbound™.